Request Trial
4 September 2026NewsRegulation & IndustryMarisa Woutersen

G 1/25: EPO settles controversial patent description question

Clarity from the Enlarged Board of Appeal for when patent descriptions must be amended to reflect changes to the claims has finally arrived. LSIPR outlines G 1/25, the debate that led to the referral and the EPC provisions at the heart of the ruling.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Regulation & Industry
California votes for law to restrict use of genAI by lawyers
4 September 2026   Lawmakers support a bill that would place guardrails on lawyers’ use of generative AI for court filings, in a bid to clamp down on AI ‘hallucinations’ and inaccuracies.
Regulation & Industry
FDA targets faster generic approvals in drive to slash drug prices
27 August 2026   Dozens of new and revised guidances could make it faster and less costly to bring generics to market, as the US ramps up pressure on drug prices.
Regulation & Industry
The buyers' wishlist: What makes a life sciences deal stack up?
25 August 2026   While promising science draws in buyers, intellectual property determines the price, terms, and viability of an agreement. LSIPR digs into what investors are looking for—and the biggest turn-offs that destroy a deal.


Editor's picks

Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
Biotech
Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
1 September 2026

Editor's picks

Biotech
Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
1 September 2026
MedTech
Abbott fends off Chinese rival’s patent challenge at UPC
18 August 2026
Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026
Regulation & Industry
Buying the brains: Why is Big Pharma shopping for innovation?
27 July 2026
Regulation & Industry
Why is 2026 already a record year for M&A activity?
17 July 2026
Biotech
Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer
15 July 2026

More features

California votes for law to restrict use of genAI by lawyers
10x Genomics wins latest round in Parse patent dispute
Sun Pharma import ban back in force after Squires intervention
White & Case life sciences co-leader moves firms
‘Busiest’ US district patent judge swaps bench for private practice
Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
Pinsents expands German patent practice with partner duo
Tempus AI bid to derail DNA patent case hits snag